Drug Profile
Transforming growth factor-beta-1 gene therapy
Latest Information Update: 26 Aug 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Gene therapies; Growth factors
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis; Transplant rejection
Most Recent Events
- 31 Jul 1998 Preclinical development for Rheumatoid arthritis in USA (IM)
- 02 Jun 1995 Preclinical development for Transplant rejection in USA (Unknown route)